Alzheimer’s Drug Coverage Issues Move To Forefront With Biogen’s Plan To Seek Approval

Any product would be mostly covered by Medicare, but because the potential patient population will likely be 'substantial,' payers will likely 'closely scrutinize' these drugs, Duke Margolis white paper observes.